Investor Meeting on Q3 FY2018 Results

from the beginning

Conference Call on Q3 FY2018 Results

Presenter：

Shigeo Taniuchi
President and Chief Operating Officer

• Santen’s Values and Mission Statement

• MTP2020 Fundamental Policy and Strategic Goals

Q3 FY2018 Financial Results ended December 31, 2018

• Q3 FY2018 Financial Overview

• Q3 FY2018 Revenue

• Q3 FY2018 Core Operating Profit

• Performance by Business (Japan)

• Performance by Business (Asia)

• Performance by Business (EMEA)

• FY2018 Forecast (No change from May 9)

• Dividend Forecast for FY2018 (No change from May 9)

Status of Research & Development

Presenter：

Naveed Shams, M.D., Ph.D.
Senior Corporate Officer
Chief Scientific Officer
Head of Global Research & Development

• Pipeline / Product Development Status (1)

• Pipeline / Product Development Status (2)

Appendix

• Q3 FY2018 Profit and Loss Statement

• Q3 FY2018 Financial Position

• Q3 FY2018 Segment Revenue

• Capital Expenditures / Depreciation & Amortization

• Prescription Ophthalmic Market in Japan

Forward-Looking Statements

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7